search icon
  • Find Practice Guidelines

    Find Practice Guidelines

    Also available:

The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.

  • Policy News


    STAAR Act

    The STAAR Act was reintroduced by Sen. Sherrod Brown this week. The bill, championed by IDSA, provides stronger federal leadership to coordinate activities that address resistance and strengthen accountability.

  • Breaking News and Alerts

    4/19/2014 11:32:23 AM

    CUBICIN (daptomycin for injection) by Cubist Pharmaceuticals: Recall - Presence of Particulate Matter

    CUBICIN (daptomycin for injection) by Cubist Pharmaceuticals: Recall - Presence of Particulate Matter [Posted 04/18/2014] AUDIENCE: Pharmacy, Patient, Health Professional, Nursing ISSUE: Cubist Pharmaceuticals, Inc. is voluntarily recalling one lot (Lot # 280453F) of CUBICIN (daptomycin for injection) 500 mg to the user level due to the presence of particulate matter, identified as glass particles. The administration of glass particulate, if present in an intravenous drug, poses a potential safety risk to patients including: thromboembolism, pulmonary emboli, phlebitis, mechanical block of the capillaries or arterioles, activation of platelets, subsequent generation of microthrombi, and emboli. Patients with preexisting condition of trauma or other medical condition that adversely affects the microvascular blood supply are at an increased risk. Administration of a glass particulate can also lead to formation of granulomas, which represent a protective local inflammatory response to the foreign material. BACKGROUND: Cubicin is an intravenously administered prescription product indicated for the treatment of skin infections and certain blood stream infections. Cubicin was distributed Nationwide to multiple consignees. RECOMMENDATION: Anyone with an existing inventory of the product lot listed should determine whether they have product from the recalled lot, quarantine and discontinue distribution of this recalled lot of the product and call Cubist at (855) 534-8309 to arrange for return and replacement of the affected lot. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report Online:  Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 Read the MedWatch safety alert, including links to the Press Release at:

    4/15/2014 9:52:13 AM

    CDC Continues to Recommend Influenza Antiviral Medications

    CDC continues to recommend the use of the neuraminidase inhibitor antiviral drugs as an important adjunct to influenza vaccination in the treatment of influenza.

    4/9/2014 11:44:07 AM

    HIV/AIDS Update - Changes to the Prezista (darunavir) label

    FDA Alert

    1/23/2014 11:18:13 AM

    Human Infection with Avian Influenza A (H5N1) Virus

  • News from IDSA and the Journals

    Stroke Risk Higher After Shingles, But Antivirals May Help

    >> Read more

    A new study in Clinical Infectious Diseases finds increased risk of stroke following shingles but suggests antiviral drugs may offer some protection.

| HIVMA | Contact Us

© Copyright IDSA 2013 Infectious Diseases Society of America

Full Site Mobile Site